| Heart disease and stroke statistics—2016 update: a report from the American Heart Association D Mozaffarian, EJ Benjamin, AS Go, DK Arnett, MJ Blaha, M Cushman, ... circulation 133 (4), e38-e360, 2016 | 74755* | 2016 |
| Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis AB Rossebø, TR Pedersen, K Boman, P Brudi, JB Chambers, K Egstrup, ... New England journal of medicine 359 (13), 1343-1356, 2008 | 2142 | 2008 |
| Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in … K Wachtell, M Lehto, E Gerdts, MH Olsen, B Hornestam, B Dahlöf, H Ibsen, ... Journal of the American College of Cardiology 45 (5), 712-719, 2005 | 1280 | 2005 |
| Prognostic significance of left ventricular mass change during treatment of hypertension RB Devereux, K Wachtell, E Gerdts, K Boman, MS Nieminen, ... Jama 292 (19), 2350-2356, 2004 | 1166 | 2004 |
| Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study H Ibsen, MH Olsen, K Wachtell, K Borch-Johnsen, LH Lindholm, ... Hypertension 45 (2), 198-202, 2005 | 1040* | 2005 |
| A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension MH Olsen, SY Angell, S Asma, P Boutouyrie, D Burger, JA Chirinos, ... The Lancet 388 (10060), 2665-2712, 2016 | 1012 | 2016 |
| Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study K Wachtell, H Ibsen, MH Olsen, K Borch-Johnsen, LH Lindholm, ... Annals of internal medicine 139 (11), 901-906, 2003 | 806 | 2003 |
| Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial RB Devereux, B Dahlöf, E Gerdts, K Boman, MS Nieminen, ... Circulation 110 (11), 1456-1462, 2004 | 733 | 2004 |
| Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant … K Rahimi, Z Bidel, M Nazarzadeh, E Copland, D Canoy, R Ramakrishnan, ... The Lancet 397 (10285), 1625-1636, 2021 | 723 | 2021 |
| Prevention of atrial fibrillation by renin-angiotensin system inhibition: a meta-analysis MP Schneider, TA Hua, M Böhm, K Wachtell, SE Kjeldsen, RE Schmieder Journal of the American College of Cardiology 55 (21), 2299-2307, 2010 | 573 | 2010 |
| Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study LH Lindholm, H Ibsen, K Borch-Johnsen, MH Olsen, K Wachtell, B Dahlöf, ... Journal of hypertension 20 (9), 1879-1886, 2002 | 563 | 2002 |
| Risk prediction is improved by adding markers of subclinical organ damage to SCORE T Sehestedt, J Jeppesen, TW Hansen, K Wachtell, H Ibsen, ... European heart journal 31 (7), 883-891, 2010 | 534 | 2010 |
| Short-and long-term cause of death in patients treated with primary PCI for STEMI F Pedersen, V Butrymovich, H Kelbæk, K Wachtell, S Helqvist, J Kastrup, ... Journal of the American College of Cardiology 64 (20), 2101-2108, 2014 | 502 | 2014 |
| Outcome of patients with low-gradient “severe” aortic stenosis and preserved ejection fraction N Jander, J Minners, I Holme, E Gerdts, K Boman, P Brudi, JB Chambers, ... Circulation 123 (8), 887-895, 2011 | 444 | 2011 |
| Carotid intima-media thickness progression as surrogate marker for cardiovascular risk: meta-analysis of 119 clinical trials involving 100 667 patients P Willeit, L Tschiderer, E Allara, K Reuber, L Seekircher, LU Gao, X Liao, ... Circulation 142 (7), 621-642, 2020 | 386 | 2020 |
| Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension PM Okin, K Wachtell, RB Devereux, KE Harris, S Jern, SE Kjeldsen, ... Jama 296 (10), 1242-1248, 2006 | 367 | 2006 |
| Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE … K Wachtell, B Hornestam, M Lehto, DJ Slotwiner, E Gerdts, MH Olsen, ... Journal of the American College of Cardiology 45 (5), 705-711, 2005 | 342 | 2005 |
| Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study E Gerdts, L Oikarinen, V Palmieri, JE Otterstad, K Wachtell, K Boman, ... Hypertension 39 (3), 739-743, 2002 | 326 | 2002 |
| Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study K Wachtell, PM Okin, MH Olsen, B Dahlöf, RB Devereux, H Ibsen, ... Circulation 116 (7), 700-705, 2007 | 322 | 2007 |
| Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial E Gerdts, K Wachtell, P Omvik, JE Otterstad, L Oikarinen, K Boman, ... Hypertension 49 (2), 311-316, 2007 | 310 | 2007 |